3.0
1 July 2020
Current employee, less than 1 year
Leiden
Recommend
CEO approval
Business outlook
Pros
Very ambitious, fast moving, greenfield
Cons
All commercial people from same 'Pharma bloodgroup' which will limit innovation and differentiation in the end